SLC5A2 and heart failure: In a recent meta-analysis study, sodium-glucose cotransporter 2 (SGLT2) inhibitor in combination with an RAS blocker induced the additional reduction of albuminuria, creatinine, cardiovascular mortality, and heart failure-related hospitalization rates vs. RAS blocker alone [35].